Inicio>>Signaling Pathways>> Immunology/Inflammation>> Reactive Oxygen Species>>Anti-inflammatory agent 38

Anti-inflammatory agent 38

Catalog No.GC70979

Anti-inflammatory agent 38 (compuesto 23d) es un potente inhibidor de la vía Nrf2/HO-1, con un valor de IC50 de 0,38 μM para NO.

Products are for research use only. Not for human use. We do not sell to patients.

Anti-inflammatory agent 38 Chemical Structure

Cas No.: 3032633-42-1

Tamaño Precio Disponibilidad Cantidad
1 mg
333,00 $
Disponible
5 mg
846,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents
Anti-inflammatory agent 38 (compound 23d) is a potent Nrf2/HO-1 pathway inhibitor, with an IC50 value of 0.38 μM for NO. Anti-inflammatory agent 38 can significantly reduce the level of ROS in cells. Anti-inflammatory agent 38 can be used for researching anti-inflammatory.

Anti-inflammatory agent 38 (compound 23d) (0.25, 0.5, 1 and 2 µM; 3 hours) can reduce ROS production in RAW264.7 cells stimulated with LPS (0.5 µg/mL LPS stimulates for 12 hours)[1].
Anti-inflammatory agent 38 (0.25, 0.5, 1 and 2 µM; 3 hours) significantly increases the expression of Nrf2 and HO-1 in LPS-stimulated RAW264.7 cells in a dose-dependent manner, and promoting LPS-induced Nrf2 nuclear translocation[1]

References:
[1]. Wang W, et al. Synthesis of lathyrane diterpenoid nitrogen-containing heterocyclic derivatives and evaluation of their anti-inflammatory activities. Bioorg Med Chem.

Reseñas

Review for Anti-inflammatory agent 38

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Anti-inflammatory agent 38

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.